MOTS-c: What It Is and What the Evidence Shows

By Victor Björk

What MOTS-c Is

MOTS-c is a 16-amino-acid peptide encoded within the 12S rRNA gene of the mitochondrial genome, placing it in a small and still-expanding class of mitochondria-derived peptides that researchers have only recently begun to characterize systematically. [1] Its origin in mitochondrial DNA rather than the nuclear genome is what makes it unusual: translated from a non-canonical open reading frame, it can translocate to the nucleus under metabolic stress to participate in mitonuclear signaling. [2] That nuclear-translocation behavior matters because MOTS-c is not simply a circulating hormone-like signal but a molecule capable of directly influencing gene expression in a stress-responsive way.

The discovery of MOTS-c belongs to the broader recognition that mitochondria are active signaling organelles, not just energy factories. [3] The peptide sits at the intersection of metabolic sensing and intercellular communication, which is why it attracted attention quickly after its initial characterization.

Why MOTS-c Shows Up in Research Discussions

Two threads drive most of the interest. The first is metabolic: MOTS-c has shown the ability to improve insulin sensitivity and glucose homeostasis in diet-induced obese mouse models, and reviews covering mitochondrial-derived microproteins consistently highlight this as one of the more reproducible preclinical findings in the area. [4] The second thread is aging: circulating MOTS-c levels appear to decline with age, and reviews of mitochondria-derived peptides in cardiovascular and aging contexts report diminished levels in older populations and in disease states, with some epidemiological data linking certain MOTS-c genetic variants to longevity. [5]

Those two threads are related mechanistically, which makes the compound appealing as a research target. Metabolic dysfunction and aging interact in ways that are still being untangled, and a peptide that seems to sit at that intersection naturally draws attention from multiple directions.

The honest framing is that the compound’s presence in peptide communities and longevity discussions currently runs ahead of what the human trial record can support. The preclinical signal is real enough to justify continued investigation, but whether it translates is a question the evidence cannot yet answer.

What the Literature Looks Like

The bulk of published MOTS-c research through 2024 consists of rodent studies and in-vitro mechanistic work. Registered human interventional trials are sparse, and the few that exist are small. There is no large randomized controlled trial of exogenous MOTS-c administration in humans as of early 2025, and that gap is the central limitation of the field right now.

On the observational side, there are human datasets worth examining. The 2021 Reynolds et al. study in Scientific Reports examined MOTS-c in the context of a 16-week aerobic and resistance exercise intervention in breast cancer survivors. [6] The finding was more specific than headlines about exercise and MOTS-c would suggest: MOTS-c levels increased significantly in Non-Hispanic White participants following exercise but not in Hispanic participants, and in the Non-Hispanic White group, post-exercise MOTS-c was associated with reductions in fat mass, body weight, HOMA-IR, and CRP, alongside increases in lean mass. [6] That is a meaningful signal, but it is also a secondary analysis in a specific patient population, so generalizing from it requires care.

Preclinical work has extended into exercise biology more broadly. Reviews of mitokines and mitochondrial stress signaling describe mitochondria-derived peptides as responsive to exercise-induced stress and as emerging mediators of healthy aging, though the specifics of MOTS-c’s exercise dynamics in mice are often grouped with the broader mitokine literature rather than reported in isolation. [7]

One area where the literature is genuinely thin: the original discovery paper, the dosing details from rodent metabolic studies, and the subcutaneous versus intraperitoneal administration comparisons in animals all had insufficient verified citation support to report specific numbers here with confidence. The claim that doses in rodent studies typically run in a particular milligram-per-kilogram range appears in secondary discussions, but the primary sources needed to anchor those specifics were not confirmable through the verification process used for this article. Anyone designing a study or reviewing the pharmacokinetics literature should go directly to the primary rodent publications rather than rely on summary figures.

What Is Actually Established vs. What Is Extrapolated

The mechanistic picture is the strongest part of the MOTS-c story. MOTS-c activates AMPK and modulates the folate cycle and purine biosynthesis pathway — grounded in cell-level work that has been replicated and reviewed, not speculative extrapolation. [3] This fits coherently within the broader understanding of mitochondria as dynamic signaling organelles that sense and transduce metabolic states.

The anti-obesity and insulin-sensitizing effects in rodents are consistent across multiple independent groups, which gives the preclinical signal reasonable credibility. Reviews covering mitochondrial-derived microproteins treat these findings as among the more reliable in the area. [4] The problem is that rodent-to-human translation in metabolic peptides has a poor historical record. GLP-1 agonists are the exception, not the template. A compound working well in diet-induced obese mice is necessary but nowhere near sufficient evidence that it will work in humans at comparable effect sizes.

Claims about MOTS-c extending human lifespan or reversing aging rest on epidemiological associations and mouse longevity data, with no interventional human evidence behind them. The longevity associations are a legitimate research lead, but they are being discussed in some corners as if they were clinical findings.

The safety picture is essentially blank. There are no published peer-reviewed data on the tolerability of exogenous MOTS-c in humans. Given that the peptide’s activity includes nuclear translocation under stress conditions, that absence is not a minor gap. A molecule that can enter the nucleus and alter gene expression in a context-dependent way deserves more than the current level of human safety characterization before it gets used widely outside of controlled trials.

The contrarian point worth making explicitly: the fact that MOTS-c is endogenous does not make exogenous administration safe by default. Endogenous origin tells you the molecule has a biological role; it tells you nothing about what happens when you administer it at pharmacological doses through a route and schedule that has no physiological precedent. Insulin is endogenous. That does not mean any dose and any timing is without consequence.

Where to Go Next

The Reynolds et al. 2021 paper in Scientific Reports is one of the more practically useful human datasets currently available, precisely because it connects MOTS-c to an intervention (exercise) that is itself well-characterized, and because it surfaces the heterogeneity in response across populations. [6] That heterogeneity is a finding, not a noise problem, and it points toward the kind of question a phase II trial would need to address.

For the mechanistic and discovery-level context, the 2022 Cell Metabolism review on mitochondrial signal transduction provides the framework for understanding where MOTS-c sits within the larger biology of mitonuclear communication. [3] The 2025 Trends in Genetics review on mitochondrial-derived microproteins is the most current synthesis of the field’s direction and is worth reading alongside it. [4]

On ClinicalTrials.gov, listings for MOTS-c interventional studies are sparse as of 2025. Any newly registered phase I trial would be a meaningful signal that the field is moving toward the kind of human data it currently lacks. The honest read on MOTS-c right now is a credible mechanism, a consistent preclinical signal, suggestive human observational data, and no interventional human evidence — and the field will stay stuck at that assessment until someone runs the trial.

[1]: Socialized mitochondria: mitonuclear crosstalk in stress. Experimental & Molecular Medicine, 2024. https://doi.org/10.1038/s12276-024-01211-4

[2]: Microproteins: Overlooked regulators of physiology and disease. iScience, 2023. https://doi.org/10.1016/j.isci.2023.106781

[4]: Mitochondrial-derived microproteins: from discovery to function. Trends in Genetics, 2025. https://doi.org/10.1016/j.tig.2024.11.010

[5]: Mitochondrial-derived peptides in cardiovascular disease: Novel insights and therapeutic opportunities. Journal of Advanced Research, 2024. https://doi.org/10.1016/j.jare.2023.11.018

[3]: Mitochondrial signal transduction. Cell Metabolism, 2022. https://doi.org/10.1016/j.cmet.2022.10.008

[7]: Mitochondrial stress and mitokines in aging. Aging Cell, 2023. https://doi.org/10.1111/acel.13770

[6]: Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Scientific Reports, 2021. https://doi.org/10.1038/s41598-021-96419-z

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.

References

1. Socialized mitochondria: mitonuclear crosstalk in stress.. Experimental & molecular medicine, 2024.

2. Microproteins: Overlooked regulators of physiology and disease.. iScience, 2023.

3. Mitochondrial signal transduction.. Cell metabolism, 2022.

4. Mitochondrial-derived microproteins: from discovery to function.. Trends in genetics : TIG, 2025.

5. Mitochondrial-derived peptides in cardiovascular disease: Novel insights and therapeutic opportunities.. Journal of advanced research, 2024.

6. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.. Scientific reports, 2021.

7. Mitochondrial stress and mitokines in aging.. Aging cell, 2023.